Rivaroxaban for preventing adverse outcomes after acute management of acute coronary
KEYWORDS: rivaroxaban, patients, aspirin, treatment, committee, coronary, company, acute, erg, trial, acute coronary, syndrome, coronary syndrome, events, dose

MI, stroke or severe recurrent ischaemia needing revascularisation â€¢ composite of CV death, MI, stroke or severe recurrent ischaemia leading to hospitalisation. 3.6 The results for the primary efficacy end point for the total trial population in ATLAS-ACS 2-TIMI 51 are provided in table 1. Table 1 Effect of rivaroxaban compared with placebo on the primary efficacy end point (total population, mITT analysis [excluding 3 sites]) 2.5 mg rivaroxaban bd 5 mg rivaroxaban bd Combined rivaroxaban Stratum versus placebo versus placebo dose versus placebo HR 0.84 HR 0.85 HR 0.84 ALL strata 95% CI 0.72 to 95% CI 0.73 to 95% CI 0.74 to 0.96 (n=15,342) 0.97 0.98 p=0.008 p=0.02 p=0.028 HR 0.74 HR 0.64 HR 0.69 Stratum 1: aspirin alone 95% CI 0.45 to 95% CI 0.38 to 95% CI 0.45 to 1.05 (n=1,050) 1.22 1.07 p=0.084 p=0.234 p=0.089 HR 0.85 HR 0.87 Stratum 2: aspirin plus HR 0.86 95% CI 0.72 to 95% CI 0.74 to clopidogrel or ticlopidine 95% CI 0.75 to 0.98 0.99 1.01 (n=14,292) p=0.024 p=0.039 p=0.075 Abbreviations: bd, twice daily; CI: confidence interval; HR: hazard ratio, mITT, modified intention to treat 3.7 In its submission, the company provided results on the primary efficacy end
